Expert InterviewWVE
Slingshot members are talking to an expert! The topic is:
A Look at the Phase 1, 6-month Data from Wave Life Sciences' INLIGHT Trial Evaluating WVE-007, an Investigational siRNA therapy, in Patients with Obesity and Type 2 Diabetes
Executed on:Apr 7, 2026 11:00 AM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: University of Pittsburgh
- Director of Endocrinology and Metabolism Clinical Research Core and Translational Research Center at UPMC.
- Treats 800- 900 obese patients per year who are at risk for major adverse cardiac events.
- Clinical interests are in the areas of diabetes and general endocrinology; Research interests in the etiology and treatment of insulin resistance in humans, medications that improve insulin resistance and beta cell function, and is currently investigating the pathogenesis of pancreatitis-related diabetes to identify new possibilities of prevention and treatment.
Interview Goal
To understand physician perspectives on the interim Phase 1 INLIGHT trial data for WVE-007 from Wave Life Sciences (NASDAQ: WVE), an investigational INHBE-targeting siRNA therapy, including interpretation of reductions in visceral fat, preservation of lean mass, and the potential clinical impact of infrequent dosing following a single administration in patients with obesity and type 2 diabetes.